CN109303333A - A kind of Halth-care composition improving sleep - Google Patents
A kind of Halth-care composition improving sleep Download PDFInfo
- Publication number
- CN109303333A CN109303333A CN201811064295.3A CN201811064295A CN109303333A CN 109303333 A CN109303333 A CN 109303333A CN 201811064295 A CN201811064295 A CN 201811064295A CN 109303333 A CN109303333 A CN 109303333A
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- walnut
- halth
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000007958 sleep Effects 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 239000000284 extract Substances 0.000 claims abstract description 103
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 34
- 235000020234 walnut Nutrition 0.000 claims abstract description 34
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 30
- 244000182067 Fraxinus ornus Species 0.000 claims abstract description 15
- 235000002917 Fraxinus ornus Nutrition 0.000 claims abstract description 15
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 15
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 15
- 210000000582 semen Anatomy 0.000 claims abstract description 14
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 9
- 240000006079 Schisandra chinensis Species 0.000 claims abstract 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 32
- 241000758789 Juglans Species 0.000 claims description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 239000003208 petroleum Substances 0.000 claims description 19
- 238000000605 extraction Methods 0.000 claims description 16
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 230000005526 G1 to G0 transition Effects 0.000 claims description 8
- 238000004185 countercurrent chromatography Methods 0.000 claims description 8
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 claims description 8
- HZQXXYJHLCSUGQ-UHFFFAOYSA-N ethyl acetate hexane methanol hydrate Chemical compound O.OC.CCCCCC.CCOC(C)=O HZQXXYJHLCSUGQ-UHFFFAOYSA-N 0.000 claims description 7
- 238000007803 cold maceration Methods 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 244000241257 Cucumis melo Species 0.000 claims description 4
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims description 4
- 244000184861 Juglans nigra Species 0.000 claims description 4
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 4
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 4
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims description 4
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 claims description 4
- 125000001033 ether group Chemical group 0.000 claims description 4
- 239000002024 ethyl acetate extract Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000052 vinegar Substances 0.000 claims 1
- 235000021419 vinegar Nutrition 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 16
- 206010039966 Senile dementia Diseases 0.000 abstract description 15
- 230000036541 health Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 3
- 241000196324 Embryophyta Species 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 240000007049 Juglans regia Species 0.000 abstract 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 28
- 238000012360 testing method Methods 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 241000218628 Ginkgo Species 0.000 description 9
- 241000256856 Vespidae Species 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000010171 animal model Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000736075 Schisandra Species 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000036578 sleeping time Effects 0.000 description 6
- 102100027831 14-3-3 protein theta Human genes 0.000 description 5
- 229960000796 barbital sodium Drugs 0.000 description 5
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 230000004620 sleep latency Effects 0.000 description 4
- 241000143437 Aciculosporium take Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 230000009189 diving Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 244000144993 groups of animals Species 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000028527 righting reflex Effects 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 206010003084 Areflexia Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention belongs to technical field of health care food, it is related to a kind of Halth-care composition for improving sleep, is grouped as by the group of following parts by weight: 25-40 parts of Walnut extract, 22-45 parts of Semen Ginkgo extract, 3-15 parts of Radix Pseudostellariae extract, 5-15 parts of Schisandra chinens P.E, 5-15 parts of Rhizoma Polygonati extract, 3-10 parts of manna oligosacchride, 1-5 parts of B6.The Halth-care composition can effectively improve sleep, improve the senile dementia state of an illness, prevent the generation of senile dementia.The formula is extracted with natural plant raw material, Semen Ginkgo extract and Walnut extract using above-mentioned technology, and the activity of active principle in product is effectively maintained.
Description
Technical field
The present invention relates to a kind of Halth-care compositions for improving sleep, belong to technical field of health care food.The composition is logical
Cross improvement sleep, effectively prevention senile dementia.
Technical background
A Ercihai Summerside sick (Alzheimer ' s Disease, abbreviation AD) is called senile dementia, is worldwide the elderly
Common disease, it is estimated that, the whole world there are about 17,000,000~25,000,000 people to suffer from this disease.Domestic statistics show China 60 years old with
On the elderly in the disease incidence of this disease be about 0.21%, over-65s 0.31%.It brings huge warp to family and society
Ji and nursing burden, account for the 4th of human death's reason.Senile dementia is a kind of central nervous system degeneration, and clinic is main
Show as the neuropsychic symptoms such as gradual memory obstacle, cognition dysfunction, personality change and aphasis, feature venereal disease
Reason is changed into amyloid beta and is deposited in the nerve cell that the extracellular senile plaque to be formed and Protein tau Hyperphosphorylationof are formed
Neurofibrillary tangles and neuron loss are with glial cells hyperplasia etc..
The pathogenesis of senile dementia is not yet clear so far.But there are many theories for its pathogenesis, such as: beta-amyloyd egg
White (A β) theory, Protein tau Hyperphosphorylationof theory etc..(1) under normal circumstances, brain and cerebrospinal fluid (cerebrospinal
Fluid, CSF) A β can be discharged, but burst size is few and is conducive to remove, and works as sleep insufficiency, when neuron is damaged,
Soluble A β burst size is excessive, and removes that dynamics is inadequate, and soluble aβ protein, which will be deposited slowly, becomes rubbish, and assembles
As A beta, and then induce senile dementia.(2) Tau albumen is the highest microtubule associated protein of content, after Hyperphosphorylationof
It will lead to cell skeleton loss of function, destroy neuronal microtubules structure, cranial nerve retrogression pathological changes are caused, so as to cause old
Dementia.
The drug of existing prevention senile dementia is also very much, for example, disclosed in CN201510162432.7 it is a kind of treat it is old
The Chinese medicine composition of dementia, for another example a kind of nutrient oatmeal for preventing senile dementia of CN201310299893.X and its preparation side
A kind of folium ginkgo health product for preventing senile dementia of method, CN201210586523.X and preparation method thereof etc., but it is existing
These compositions or health care product, effect is undesirable, and tracing it to its cause may be not from the pathogenesis of senile dementia
It is basic to go to solve.
Summary of the invention
The present invention will provide a kind of Halth-care composition for improving sleep, by improving sleep realization to the morning of senile dementia
Phase prevention.
From amyloid beta (A β) theory, discovery improves sleep or A β can be improved in increase deep sleep (REM) time
Clearance rate；
From Protein tau Hyperphosphorylationof theory, it is found that when obstacle occur in AD patient sleeps, many sleep regulation regions (such as it is blue
Spot, nuclei of median raphe, nodular nipple nucleus, parabrachial nuclei and basal forebrain) in there is abnormal Protein tau phosphorylation, disclose sleep barrier
Hinder closely related with Protein tau phosphorylation namely related with senile dementia.
Speculate by improve sleep health can early intervention or mitigate AD morbidity effective means.
The present invention adopts the following technical scheme that:
A kind of Halth-care composition improving sleep, is grouped as: 25-40 parts of Walnut extract, gingko by the group of following parts by weight
22-45 parts of extract, 3-15 parts of Radix Pseudostellariae extract, 5-15 parts of Schisandra chinens P.E, 5-15 parts of Rhizoma Polygonati extract, manna oligosacchride
3-10 parts, 1-5 parts of B6.
It is preferred that a kind of Halth-care composition for improving sleep, is grouped as: Walnut extract 30 by the group of following parts by weight
Part, 30 parts of Semen Ginkgo extract, 10 parts of Radix Pseudostellariae extract, 10 parts of Schisandra chinens P.E, 10 parts of Rhizoma Polygonati extract, manna oligosacchride 8
Part, B62 parts.
It is preferred that the Semen Ginkgo extract the preparation method is as follows: A. takes water content in 15% dry gingko benevolence below, powder
It is broken, it is extracted 3 times with alcohol reflux, 2 h, filtration recycle Extraction solvent, obtain gingko medicinal extract every time；B. gingko medicinal extract is suspended in
In water, uses respectively successively with isometric petroleum ether, ethyl acetate, extracting n-butyl alcohol 3 times, merges each section extract liquor respectively,
Solvent is recovered under reduced pressure, obtains each position gingko medicinal extract；C. ethyl acetate extract gingko medicinal extract is taken, is divided using high performance countercurrent chromatography
From purifying, upper phase is stationary phase, and lower phase is mobile phase, carries out isolated Semen Ginkgo extract.
It is preferred that dicyandiamide solution is chloroform-methanol-water=4:3:2 (V:V:V) or n-hexane-ethyl acetate-first in step C
Alcohol-water=4:5:3:5 (V:V:V:V).
It is preferred that the Walnut extract the preparation method is as follows: a. is dry by walnut kernel, sufficiently crush, then take walnut kernel
Powder is extracted 3 times using cold-maceration, and extraction time is respectively 48h, 48h, for 24 hours, combined extract, and concentration obtains walnut leaching
Cream；B. walnut medicinal extract is suspended in water, with isometric petroleum ether extraction 3 times, takes petroleum ether layer, be concentrated under reduced pressure, obtain stone
Oily ether phase medicinal extract；C. water layer is extracted 3 times with isometric acetic acid ethyl ester again, takes ethyl acetate layer, is concentrated under reduced pressure, is obtained acetic acid second
Cruel phase medicinal extract；D. petroleum ether part medicinal extract and the cruel phase medicinal extract of acetic acid second merge, and are isolated and purified using high performance countercurrent chromatography,
Dicyandiamide solution is n-hexane-ethyl acetate-methanol-water=1:10:1:10 (V:V:V:V), and upper phase is stationary phase, and lower phase is flowing
Phase carries out isolated walnut mixed extract.
It is preferred that the Extraction solvent of cold-maceration is methanol, the mixing ratio of walnut kernel powder and methanol is 1:4.
It is preferred that the manna oligosacchride is the manna oligosacchride extracted from melon bean gum.
By implementing above-mentioned technical proposal, technical effect of the invention is as follows: the Halth-care composition can effectively improve
Sleep improves the senile dementia state of an illness, prevents the generation of senile dementia.The formula is with natural plant raw material, Semen Ginkgo extract and core
Peach extract is extracted using above-mentioned technology, effectively maintains the activity of active principle in product.
Specific embodiment
The present invention is further elaborated with by following instance, further describes various aspects of the invention, but answer
The understanding, the range that following instance is not intended to restrict the invention.
Embodiment 1:
A kind of Halth-care composition improving sleep, is grouped as by the group of following parts by weight: 40 parts of Walnut extract, gingko are extracted
35 parts of object, 3 parts of Radix Pseudostellariae extract, 15 parts of Schisandra chinens P.E, 12 parts of Rhizoma Polygonati extract, 3 parts of manna oligosacchride, 5 parts of B6.
Embodiment 2:
A kind of Halth-care composition improving sleep, is grouped as by the group of following parts by weight: 30 parts of Walnut extract, gingko are extracted
30 parts of object, 10 parts of Radix Pseudostellariae extract, 10 parts of Schisandra chinens P.E, 10 parts of Rhizoma Polygonati extract, 8 parts, B62 parts of manna oligosacchride.
The Semen Ginkgo extract the preparation method is as follows: A. takes water content in 15% dry gingko benevolence below, crush, use
Alcohol reflux extracts 3 times, and 2 h, filtration recycle Extraction solvent, obtain gingko medicinal extract every time；B. gingko medicinal extract is suspended in water,
Respectively with successively with isometric petroleum ether, ethyl acetate, extracting n-butyl alcohol 3 times, merging each section extract liquor, is depressurized back respectively
Solvent is received, each position gingko medicinal extract is obtained；C. ethyl acetate extract gingko medicinal extract is taken, separate using high performance countercurrent chromatography pure
Change, dicyandiamide solution be chloroform-methanol-water=4:3:2 (V:V:V) or n-hexane-ethyl acetate-methanol-water=4:5:3:5 (V:
V:V:V), upper phase is stationary phase, and lower phase is mobile phase, carries out isolated Semen Ginkgo extract.
Embodiment 3:
A kind of Halth-care composition improving sleep, is grouped as by the group of following parts by weight: 25 parts of Walnut extract, gingko are extracted
45 parts of object, 13 parts of Radix Pseudostellariae extract, 5 parts of Schisandra chinens P.E, 15 parts of Rhizoma Polygonati extract, 8 parts of manna oligosacchride, 1 part of B6 are sweet
Revealing oligosaccharides is the manna oligosacchride extracted from melon bean gum
The Walnut extract the preparation method is as follows: a. is dry by walnut kernel, sufficiently crush, then take walnut kernel powder, use
Methanol cold-maceration extracts 3 times, methanol, and the mixing ratio of walnut kernel powder and methanol is 1:4, extraction time be respectively 48h, 48h,
For 24 hours, combined extract, concentration, obtains walnut medicinal extract；B. walnut medicinal extract is suspended in water, with isometric petroleum ether extraction 3
It is secondary, petroleum ether layer is taken, is concentrated under reduced pressure, obtains petroleum ether phase medicinal extract；C. water layer is extracted 3 times with isometric acetic acid ethyl ester again, is taken
Ethyl acetate layer is concentrated under reduced pressure, obtains the cruel phase medicinal extract of acetic acid second；D. petroleum ether part medicinal extract and the cruel phase medicinal extract of acetic acid second merge,
Isolated and purified using high performance countercurrent chromatography, dicyandiamide solution be n-hexane-ethyl acetate-methanol-water=1:10:1:10 (V:V:
V:V), upper phase is stationary phase, and lower phase is mobile phase, carries out isolated walnut mixed extract.
Embodiment 4:
A kind of Halth-care composition improving sleep, is grouped as by the group of following parts by weight: 30 parts of Walnut extract, gingko are extracted
22 parts of object, 15 parts of Radix Pseudostellariae extract, 5 parts of Schisandra chinens P.E, 6 parts of Rhizoma Polygonati extract, 10 parts of manna oligosacchride, 4 parts of B6 are sweet
Revealing oligosaccharides is the manna oligosacchride extracted from melon bean gum
The Semen Ginkgo extract the preparation method is as follows: A. takes water content in 15% dry gingko benevolence below, crush, use ethyl alcohol
Refluxing extraction 3 times, 2 h, filtration recycle Extraction solvent, obtain gingko medicinal extract every time；B. gingko medicinal extract is suspended in water, respectively
With successively with isometric petroleum ether, ethyl acetate, extracting n-butyl alcohol 3 times, merging each section extract liquor, is recovered under reduced pressure molten respectively
Agent obtains each position gingko medicinal extract；C. ethyl acetate extract gingko medicinal extract is taken, is isolated and purified using high performance countercurrent chromatography, it is molten
Agent system be chloroform-methanol-water=4:3:2 (V:V:V) or n-hexane-ethyl acetate-methanol-water=4:5:3:5 (V:V:V:
V), upper phase is stationary phase, and lower phase is mobile phase, carries out isolated Semen Ginkgo extract.
The Walnut extract the preparation method is as follows: a. is dry by walnut kernel, sufficiently crush, then take walnut kernel powder,
Extracted 3 times using methanol cold-maceration, methanol, the mixing ratio of walnut kernel powder and methanol is 1:4, extraction time be respectively 48h,
48h, for 24 hours, combined extract, concentration obtain walnut medicinal extract；B. walnut medicinal extract is suspended in water, with isometric petroleum ether
Extraction 3 times, takes petroleum ether layer, is concentrated under reduced pressure, obtains petroleum ether phase medicinal extract；C. water layer is again with isometric acetic acid ethyl ester extraction 3
It is secondary, ethyl acetate layer is taken, is concentrated under reduced pressure, obtains the cruel phase medicinal extract of acetic acid second；D. petroleum ether part medicinal extract and the cruel phase medicinal extract of acetic acid second
Merge, isolated and purified using high performance countercurrent chromatography, dicyandiamide solution is n-hexane-ethyl acetate-methanol-water=1:10:1:10
(V:V:V:V), upper phase is stationary phase, and lower phase is mobile phase, carries out isolated walnut mixed extract.
Improvement sleep is carried out to the obtained composition of embodiment 4, improves memory test test
Improve sleep experiments
1 test example 1: improve sleep function animal experiment
2 experiment purposes: whether have the function of improving sleep by experimental verification product.According to the Ministry of Public Health " health care product examine with
Assessment technique specification " in improve sleep detection method carry out.
3 experimental materials:
3.1 samples: embodiment 4, human oral's recommended amounts are each 0.2g 2 times a day.Adult weight converts into small according to 60kg
Mouse dosage about 0.6mg/ times.
3.2 experimental animals: SPF grades of ICR mouse, 240, weight (20 ± 2) g.
3.3 main agents: carbrital, barbital sodium.
3.4 experimental situations: cleaning grade experimental animal environmental facility, 20 DEG C -22 DEG C of raising temperature, relative humidity 55%-
65%。
4 experimental methods and result
The configuration of 4.1 samples and dosage selection: Example 4 is appropriate, adds distilled water to make to dissolve, being configured to dosage is respectively low dose
Amount 300mg/kg.BW, middle dosage 600mg/kg.BW, high dose 900mg/kg.BW(are respectively equivalent to human body recommended intake
10 times, 20 times, 30 times) given the test agent.Stomach-filling capacity is 0.2ml/20g.BW
4.2 direct sleep laboratories
Mouse 48 are taken, is randomly divided into four groups, respectively high, medium and low dose of test group and negative control group, test component be not right
The test solution of dosage is answered, negative control group gives the distilled water of same isometric(al), and daily oral stomach-filling is given tested material 1 time, even
It is continuous to give 30 days, after last gives tested material, sleep latency is denoted as with sleeping duration, with righting reflex loss
Duration be denoted as sleeping time, it is existing whether observation each dosage group and negative control group mouse within 1 hour sleep occur
As record negative control group and each tested group of sleep mouse quantity and sleeping time.
Interpretation of result: negative control group and tested group each as seen from the above table does not occur directly to sleep during test existing
As.Show that given the test agent acts on mouse without direct sleep.
The test of 4.3 yellow Jackets Sleeping Time Prolong Eds
The grouping of experimental animal and administration with 4.2, animal last to test solution give and distilled water after, penetrated to groups of animals abdominal cavity
Yellow Jackets, yellow Jackets dosage are 45mg/kg BW, and injection volume is 0.2mL/20g BW, by above-mentioned experimental method, are seen
Can examine tested extend yellow Jackets sleeping time.
Interpretation of result: tested group of middle dosage and high dose test component are not compared with negative control group as seen from the above table, and two
A tested group of sleeping time, which extends, significant difference.When showing that given the test agent is able to extend the sleep of yellow Jackets
Between.
4.4 yellow Jackets cut off from lower dosage hypnosis test
The packet mode and administration mode of mouse first carry out trial test, determine yellow Jackets maximum threshold with 4.1 before formal test
Lower hypnotic dose is 26mg/kg BW, i.e. the yellow Jackets maximum sub-threshold dose that 85% mouse righting reflex does not disappear.Animal end
It is secondary give tested material after, groups of animals be injected intraperitoneally 0.2mL/20g yellow Jackets maximum subthreshold hypnotic dosage, record 30
It falls asleep in minute (righting reflex loss up to 1 minute or more person) number of animals.
Interpretation of result: compared with negative control group, sleep incidence improves (P < 0.05) to high dose group as seen from the above table.
4.5 barbital sodium Sleep Latency Tests
The grouping and administration of experimental animal first carry out trial test before doing formal test, determine animal 100% with 4.1
It falls asleep, but does not make dosage (the 260mg/kg BW, with this dosage formal test of sleeping time too long barbital sodium.It is dynamic
Object last given to test solution and distilled water after ten minutes, to groups of animals intraperitoneal injection 0.2mL/20g barbital sodium, by upper
Experimental method is stated, influence of the tested material to barbital sodium Sleep latency is observed.
Interpretation of result: Sleep latency has group difference (P < 0.05).Compared with negative control group, high dose group mice sleep is latent
The volt phase is obviously shortened (P < 0.05), in, low dose group mice sleep incubation period, there was no significant difference.
The test of 4.6 weight
The grouping of experimental animal weighs mouse weight before being administered with 4.2, is administered 30 days by 4.2 lower methods, after administration terminates
The weight of each mouse is weighed, mouse weight is compared between each dosage group and negative control group.
Interpretation of result: mice weights no significant difference before being administered, after administration between each dosage group mouse weight and negative control group into
Relatively also there was no significant difference for row, shows given the test agent on the weight of mouse without influence.
Improve memory mouse experiment
Weight 18-22g Kunming mouse is selected, at constant temperature (21-23 DEG C), constant humidity (45-65%), each 12 hours light and shade periods
Receptacle is tested under conditions of raising with 5 mouse of gender with cage.It will be fed with pellet, free water.
1 test example 1: improve memory function animal experiment
2 experiment purposes: whether have the function of improving sleep by experimental verification product.According to the Ministry of Public Health " health care product examine with
Assessment technique specification " in improve sleep detection method carry out.
3 experimental materials:
3.1 samples: human oral's recommended amounts are each 2g 2 times a day.Adult weight converts into dosage about 6mg/ according to 60kg
It is secondary.
3.2 experimental animals: healthy Kunming kind normal mouse 20, memory acquisition disturbance model mice caused by eastern hyoscine
(referred to as: " AD mouse ") 80, weight (20 ± 2) g.
3.3 main agents: Piracetam
3.4 experimental situations: cleaning grade experimental animal environmental facility, 20 DEG C -22 DEG C of raising temperature, relative humidity 55%-65%.
4 experimental methods and result
The configuration of 4.1 samples and dosage selection: Example composition adds distilled water to make to dissolve, and being configured to dosage is respectively low dose
Amount 300mg/kg.BW, middle dosage 600mg/kg.BW, 900 mg/kg.BW(of high dose are respectively equivalent to human body recommended intake
10 times, 20 times, 30 times) given the test agent.Stomach-filling capacity is 0.2ml/20g.BW
Step dow n test
Each group mouse is individually positioned on diving tower instrument, and voltage maintains 36V, and balancing run when training first adapts to environment 3 minutes,
After be powered, after mouse is shocked by electricity, majority jumps onto diving tower, escapes electric shock.That jumps off is considered as wrong reaction, training 5 minutes, record 5
Errors number in minute.It is retested after 24 hours, record mouse jumps off the time (incubation period) for the first time, and record is jumped in 5 minutes
Lower number (i.e. errors number), and as memory index.
Water maze
Water temperature in the lost case of mouse Y type water is maintained 25-27 DEG C, about 10 centimetres of the depth of water.Each group mouse is grouped respectively and is put into
It is trained during water is lost, mouse is put down gently upstream face and arrived in 15 seconds with it from long arm end tail is fond of food that is not salty to Y type fork when training
Platform is correct response, repeats training after resting 15 seconds after mouse arrival platform, continuous training 3 times.Record mouse is from entering water
Time and correct response number are swum out of to platform is arrived at.24, which as a child tested its memory, keeps situation, and memory is tested after 48 hours
Consolidate situation.
It is observed by mouse diving tower, water maze laboratory, solid beverage of the present invention feeds mouse for a long time, it is small to can obviously improve AD
The symptom of mouse, the present composition have the function of protection, consolidate and reproduce memory.
Claims (7)
1. a kind of Halth-care composition for improving sleep, which is characterized in that the component including following parts by weight: Walnut extract
25-40 parts, 22-45 parts of Semen Ginkgo extract, 3-15 parts of Radix Pseudostellariae extract, 5-15 parts of Schisandra chinens P.E, Rhizoma Polygonati extract 5-
15 parts, 3-10 parts, B61-5 parts of manna oligosacchride.
2. a kind of Halth-care composition for improving sleep according to claim 1, which is characterized in that including following parts by weight
Component: 30 parts of Walnut extract, 30 parts of Semen Ginkgo extract, 10 parts of Radix Pseudostellariae extract, 10 parts of Schisandra chinens P.E, rhizoma polygonati extract
10 parts of object, 8 parts, B62 parts of manna oligosacchride.
3. a kind of Halth-care composition for improving sleep according to claim 1, which is characterized in that the Semen Ginkgo extract
The drying process the preparation method is as follows: A. learns from else's experience, water content are crushed in 13% gingko benevolence below, extract 3 times with alcohol reflux, often
Secondary 2 h, filtration recycle Extraction solvent, obtain gingko medicinal extract；B. gingko medicinal extract is suspended in water, respectively with successively with isometric
Petroleum ether, ethyl acetate, extracting n-butyl alcohol 3 times, respectively merge each section extract liquor, solvent is recovered under reduced pressure, it is white to obtain each position
Fruit medicinal extract；C. ethyl acetate extract gingko medicinal extract is taken, is isolated and purified using high performance countercurrent chromatography, dicyandiamide solution is positive oneself
Alkane-acetate-methanol-water=4:5:3:5 (V:V:V:V), upper phase are stationary phase, and lower phase is mobile phase, after sample introduction 50min,
Fraction is collected, fraction is subjected to purification process, obtains Semen Ginkgo extract.
4. a kind of Halth-care composition for improving sleep according to claim 3, which is characterized in that in step C, dicyandiamide solution
For chloroform-methanol-water=4:3:2 (V:V:V) or n-hexane-ethyl acetate-methanol-water=4:5:3:5 (V:V:V:V).
5. a kind of Halth-care composition for improving sleep according to claim 1, which is characterized in that the Walnut extract
The preparation method is as follows: a. is dry by walnut kernel, sufficiently crush, then take walnut kernel powder, extracted 3 times using cold-maceration, when extraction
Between be respectively 48h, 48h, for 24 hours, combined extract, concentration obtains walnut medicinal extract；B. walnut medicinal extract is suspended in water, with etc.
The petroleum ether extraction of volume 3 times, takes petroleum ether layer, is concentrated under reduced pressure, obtains petroleum ether phase medicinal extract；C. water layer uses isometric second again
Sour second vinegar extracts 3 times, takes ethyl acetate layer, is concentrated under reduced pressure, obtains the cruel phase medicinal extract of acetic acid second；D. petroleum ether part medicinal extract and second
The sour cruel phase medicinal extract of second merges, and is isolated and purified using high performance countercurrent chromatography, and dicyandiamide solution is n-hexane-ethyl acetate-methanol-
Water=1:10:1:10 (V:V:V:V), upper phase are stationary phase, and lower phase is mobile phase, after sample introduction 55min, collect fraction, by fraction into
Row purification process carries out isolated walnut mixed extract.
6. a kind of Halth-care composition for improving sleep according to claim 5, which is characterized in that the Extraction solvent of cold-maceration
For methanol, the solid-liquid ratio of walnut kernel powder and methanol is 1:4.
7. according to claim 1 it is a kind of improve sleep Halth-care composition, which is characterized in that the manna oligosacchride be from
The manna oligosacchride extracted in melon bean gum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811064295.3A CN109303333A (en) | 2018-09-12 | 2018-09-12 | A kind of Halth-care composition improving sleep |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811064295.3A CN109303333A (en) | 2018-09-12 | 2018-09-12 | A kind of Halth-care composition improving sleep |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109303333A true CN109303333A (en) | 2019-02-05 |
Family
ID=65224874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811064295.3A Pending CN109303333A (en) | 2018-09-12 | 2018-09-12 | A kind of Halth-care composition improving sleep |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109303333A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116172194A (en) * | 2021-11-28 | 2023-05-30 | 南京艾德凯腾生物医药有限责任公司 | Health food containing broad bean pod extract and application thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1680392A (en) * | 2005-01-07 | 2005-10-12 | 上海同田生化技术有限公司 | Preparation of high-purity ginkgolide |
| CN101491577A (en) * | 2008-11-27 | 2009-07-29 | 北京宏泰康达医药科技有限公司 | Health-care product capable of improving sleep |
| CN102250108A (en) * | 2011-06-07 | 2011-11-23 | 南京泽朗农业发展有限公司 | Method for purifying byak-angelicin |
| CN103145677A (en) * | 2013-02-27 | 2013-06-12 | 中山火炬职业技术学院 | Method for separating active ingredients from aquilaria sinensis lamina by utilizing high-speed countercurrent chromatography |
| CN105145997A (en) * | 2015-09-26 | 2015-12-16 | 贵州省施秉县万富农业科技发展有限公司 | Radix pseudostellariae sealwort tea and making method thereof |
| CN106106934A (en) * | 2016-06-30 | 2016-11-16 | 成都永安制药有限公司 | A kind of health protecting tea and preparation method thereof |
| CN107373316A (en) * | 2017-07-27 | 2017-11-24 | 贵州省贝真食业有限公司 | A kind of bionical meat of pure plant and its processing method for lifting sleep quality and strengthening brain function |
| CN107432473A (en) * | 2017-09-21 | 2017-12-05 | 珠海霍普金斯医药研究院股份有限公司 | A kind of functional food for being used to prevent senile dementia |
| CN107569612A (en) * | 2017-09-14 | 2018-01-12 | 贵阳中医学院 | A kind of medicine for improving sleep and preparation method thereof |
-
2018
- 2018-09-12 CN CN201811064295.3A patent/CN109303333A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1680392A (en) * | 2005-01-07 | 2005-10-12 | 上海同田生化技术有限公司 | Preparation of high-purity ginkgolide |
| CN101491577A (en) * | 2008-11-27 | 2009-07-29 | 北京宏泰康达医药科技有限公司 | Health-care product capable of improving sleep |
| CN102250108A (en) * | 2011-06-07 | 2011-11-23 | 南京泽朗农业发展有限公司 | Method for purifying byak-angelicin |
| CN103145677A (en) * | 2013-02-27 | 2013-06-12 | 中山火炬职业技术学院 | Method for separating active ingredients from aquilaria sinensis lamina by utilizing high-speed countercurrent chromatography |
| CN105145997A (en) * | 2015-09-26 | 2015-12-16 | 贵州省施秉县万富农业科技发展有限公司 | Radix pseudostellariae sealwort tea and making method thereof |
| CN106106934A (en) * | 2016-06-30 | 2016-11-16 | 成都永安制药有限公司 | A kind of health protecting tea and preparation method thereof |
| CN107373316A (en) * | 2017-07-27 | 2017-11-24 | 贵州省贝真食业有限公司 | A kind of bionical meat of pure plant and its processing method for lifting sleep quality and strengthening brain function |
| CN107569612A (en) * | 2017-09-14 | 2018-01-12 | 贵阳中医学院 | A kind of medicine for improving sleep and preparation method thereof |
| CN107432473A (en) * | 2017-09-21 | 2017-12-05 | 珠海霍普金斯医药研究院股份有限公司 | A kind of functional food for being used to prevent senile dementia |
Non-Patent Citations (4)
| Title |
|---|
| 张万义: "《睡眠障碍实用良方》", 31 May 2016, 中国医药科技出版社 * |
| 张季声: "《睡得好，人不老》", 30 June 2017, 黑龙江科学技术出版社 * |
| 李宁: "《家常食材养全家》", 30 September 2016, 中国轻工业出版社 * |
| 陈金铭: "银杏种子化学成分研究", 《辽宁中医药大学学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116172194A (en) * | 2021-11-28 | 2023-05-30 | 南京艾德凯腾生物医药有限责任公司 | Health food containing broad bean pod extract and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078460B (en) | Traditional Chinese medicine for preventing and treating Alzheimer disease and preparation method thereof | |
| CN101168025B (en) | Medicine composition for preventing and treating senile dementia | |
| CN105920476B (en) | Traditional Chinese medicine composition for preventing and treating Alzheimer disease and preparation method thereof | |
| CN101721567A (en) | Grassleaf sweetflag rhizome extract, preparation method and application thereof | |
| CN104922164A (en) | Composite medicine preparation for treating alzheimer disease | |
| JP6440631B2 (en) | Algal extracts containing sulfated and non-sulfated polyanionic polysaccharides and uses thereof | |
| CN102894152B (en) | Health-care tea and preparation method thereof | |
| CN109303333A (en) | A kind of Halth-care composition improving sleep | |
| CN102935100A (en) | Preparation method and applications of queen lagerstroemia folium apocyni veneti general flavones | |
| Ibrahim et al. | Modulation of gastric motility and gastric lesion formation in stressed rats given enteral supplementation of palm vitamin E and a-tocopherol | |
| CN111437323A (en) | Application of vine tea extract in medicine for preventing and treating Alzheimer disease | |
| CN103040905B (en) | Herba arenariae kansuensis or the purposes of its extract in the antidotal medicine of preparation or health food | |
| CN104305192A (en) | Functional food for improving memory of Alzheimer's Disease patient and preparation method of functional food | |
| KR101509056B1 (en) | Composition having brain function and congnition enhancing activity comprising ginseng mixed herbal extracts, ginsenoside Rg2 and ginsenoside F2 | |
| CN102813646B (en) | Application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis, homomangiferin pharmaceutical compositions and homomangiferin preparations | |
| KR101476750B1 (en) | Composition comprising Muskrat musk for protection of brain cell and prevention or treatment of brain disease | |
| CN100545163C (en) | A kind of active ingredient of Chinese herbs compound and preparation and purposes of preventing and treating senile dementia | |
| CN102266428A (en) | Anti-ageing Chinese medicinal composition and preparation method and application thereof | |
| CN102188461A (en) | Application of screwtree root extractive in the preparation of anti-HBV medicament | |
| CN108478715A (en) | A kind of Chinese medicine composition is preparing the application in treating children's hyperkinetic syndrome drug | |
| CN105327331A (en) | Composition for treating and preventing senile dementia and preparation method and application of composition for treating and preventing senile dementia | |
| CN112826838B (en) | Application of kohlrabi or extract thereof | |
| CN114469967B (en) | Application of atractyloside A and derivatives thereof in preparation of anxiolytic and antidepressant drugs | |
| CN102058787B (en) | Anxiolytic drug and preparation method thereof | |
| CN109021135A (en) | A kind of codonopsis pilosula var. modesta polysaccharide formulation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190205 |
|
| RJ01 | Rejection of invention patent application after publication |